SXTP · 60 Degrees Pharmaceuticals, Inc.
$1.02
-0.06 (-5.56%)
At close · Sep 1
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated these conditions and its plans to mitigate them and concluded that, collectively, such plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern for at least one year after the date these consolidated condensed financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$3.62M
Shares
3.52M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Geoffrey Dow | President and Chief Executive Officer (Principal Executive Officer) | $727,750 |
| Kristen Landon | Chief Commercial Officer | $311,791 |
| Tyrone Miller | Chief Financial Officer (Principal Financial and Accounting Officer) | $283,250 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Kristen Landon | Chief Commercial Officer | $470,862 |
| Geoffrey Dow | President and Chief Executive Officer (Principal Executive Officer) | $323,425 |
| Tyrone Miller | Chief Financial Officer (Principal Financial and Accounting Officer) | $284,525 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Tyrone Miller | Chief Financial Officer (Principal Financial and Accounting Officer) | $135,632 |
| Geoffrey Dow | President and Chief Executive Officer (Principal Executive Officer) | $125,555 |
| Kristen Landon | Chief Commercial Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Tyrone Miller | Chief Financial Officer (Principal Financial and Accounting Officer) | $148,672 |
| Geoffrey Dow | President and Chief Executive Officer (Principal Executive Officer) | $54,510 |
| Kristen Landon | Chief Commercial Officer | — |
Key facts
CIK
1946563
CUSIP
83006G500
13F (30d)
11 filings
11 filers
Visit website
Investor relations